ReviewViruses2021
Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.
Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis.Viruses · 2024Pooled it
- High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.Journal of gastroenterology · 2023Trial
- A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection.Journal of viral hepatitis · 2023Trial
- [Distribution of serum HBV RNA in the natural history of chronic HBV infection and factors influencing HBV RNA negativity: a retrospective study stratified by HBeAg status].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Advances in Rapid Nucleic Acid Diagnostics for Hepatitis B and C Viruses: A Comprehensive Review.Reviews in medical virology · 2026Review
- A sequence-specific, nanoparticle-based biosensor platform for rapid and visual identification of serum hepatitis B virus pregenomic RNA in chronic hepatitis B patients.Microbiology spectrum · 2026Article
- Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing.Diagnostics (Basel, Switzerland) · 2025Review
- Association Between Serum HBV DNA Levels and CCL-20, CD8a, CXCL-16, and GDF-15 in Patients with Chronic Hepatitis B.Viruses · 2025Article
- Emerging Serum Biomarkers for Chronic Hepatitis B: Focus on Serum HBV RNA and HBcrAg.Journal of clinical and translational hepatology · 2025Review
- High sensitivity detection of Hepatitis B virus RNA based on 3D-DNA nanomachine and protein nanopore sensing.Molecular biomedicine · 2025Article
- Profiles and kinetics of PgRNA and clinical characteristics in pregnant, postpartum, and non-pregnant women with chronic HBV infection.Virology journal · 2025Article
- Hepatitis B Virus Variants and Cytokine Patterns in Acute Liver Failure and Transplant-Free Survival.Liver international : official journal of the International Association for the Study of the Liver · 2025Observational
- A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B.PLoS computational biology · 2025Article
- The Management of Chronic Hepatitis B: 2025 Guidelines Update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada.Canadian liver journal · 2025Article
- Functional Cure for Hepatitis B Virus: Challenges and Achievements.International journal of molecular sciences · 2025Review
- Development of Low-Cost In-House Assays for Quantitative Detection of HBsAg, HBeAg, and HBV DNA to Enhance Hepatitis B Virus Diagnostics and Antiviral Screening in Resource-Limited Settings.Pathogens (Basel, Switzerland) · 2025Article
- Transfusion-transmitted occult hepatitis B virus infection: current understanding, challenges, and its implication in blood safety.Frontiers in immunology · 2025Review
- Editorial: Chronic hepatitis B management: current status and future directions.Frontiers in medicine · 2025Article
- A study on pregenomic RNA and factors in the pregnant and postpartum women with chronic HBV infection based on real world.Frontiers in cellular and infection microbiology · 2025Article
- Characterisation of HBV and co-infection with HDV and HIV through spatial transcriptomics.eGastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even though an approved vaccine for hepatitis B virus (HBV) is available and widely used, over 257 million individuals worldwide are living with chronic hepatitis B (CHB) who require monitoring of treatment response, viral activity, and disease progression to reduce their risk of HBV-related liver disease. There is currently a lack of predictive markers to guide clinical management and to allow treatment cessation with reduced risk of viral reactivation. Novel HBV biomarkers are in development in an effort to improve the management of people living with CHB, to predict disease outcomes of CHB, and further understand the natural history of HBV. This review focuses on novel HBV biomarkers and their use in the clinical setting, including the description of and methodology for quantification of serum HBV RNA, hepatitis B core-related antigen (HBcrAg), quantitative hepatitis B surface antigen (qHBsAg), including ultrasensitive HBsAg detection, quantitative anti-hepatitis B core antigen (qAHBc), and detection of HBV nucleic acid-related antigen (HBV-NRAg). The utility of these biomarkers in treatment-naïve and treated CHB patients in several clinical situations is further discussed. Novel HBV biomarkers have been observed to provide critical clinical information and show promise for improving patient management and our understanding of the natural history of HBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.